Zydus Lifesciences has reduced the goods and services tax (GST) demands, aiming to ease financial burdens for their business operations. This GST cut is expected to bring relief to the company's tax liabilities.

The pharmaceutical company Zydus Lifesciences experienced a significant drop of 3.6%, closing at Rs.864.25, with Sensex only declining by 0.3%. This dip may be due to bearish signals and an increase in open interest, suggesting that investors should exercise caution regarding this mid-cap stock.

Zydus Lifesciences has been ordered to pay a tax demand of INR 14.2 million due to allegations of reversing inadmissible input tax credit. The company intends to file an appeal against the decision.